Guest guest Posted March 11, 2009 Report Share Posted March 11, 2009 Xopenex Sepracor Settles Xopenex Inhalation Solution Patent Infringement Litigation With Barr Laboratories, Teva Pharmaceuticals Sepracor Inc. announced a settlement and license agreement deal with Teva Pharmaceuticals USA, Inc. and Barr Laboratories, Inc., a wholly owned subsidiary of Teva, to resolve the patent infringement lawsuit against Barr. The settlement relates to Sepracor's Xopenex - levalbuterol HCl Inhalation Solution products of the dosage of 1.25 mg/3 ml, 0.63 mg/3 ml and 0.31 mg/3 ml and to grant a license to Barr and Teva. Under that agreement, Barr and Teva are permitted to launch generic versions of XOPENEX Inhalation Solution dosages under terms of a non-exclusive license commencing on February 17, 2013. http://www.rttnews.com/ArticleView.aspx?Id=878124 & SMap=1 Alana Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.